Drugs / CD19 Universal CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06691152 | Oct 2024 → Sep 2027 expected | systemic lupus erythematosus | The Children's Hospital of Zhejiang University School of Medicine | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19 Universal CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06691152 ↗ |
| Modality | Cell therapy | “CD19 chimeric antigen receptor (CAR) T cells” PMID 38381673 ↗ Feb 2024 |
| Target | CD19 | “CD19 chimeric antigen receptor (CAR) T cells” PMID 38381673 ↗ Feb 2024 |